Invited Editorials
Vol. 1 No. 1 (2022)
Gene transfer in hemophilia A: not cogent yet
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 20 April 2022
2250
Views
291
Downloads
Authors
The phase 3 clinical study of gene transfer in hemophilia A using the BioMarin vector AAV5-hFVIII-SQ (also identified as valoctocogene roxaparvovec) recently reported the results obtained in as many as 134 adult men with severe hemophilia A, so that it is at the moment the largest gene transfer study ever conducted in a rare monogenic disorder [...].
Downloads
Download data is not yet available.
Citations
Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med 2022;386:1013-25. DOI: https://doi.org/10.1056/NEJMoa2113708
Thornburg CD. Prepare the way for hemophilia A gene therapy. N Engl J Med 2022;386:1081-2. DOI: https://doi.org/10.1056/NEJMe2200878
Mannucci PM. Miracle of haemophilia drugs: personal views about a few main players. Haemophilia 2018;24:557-52. DOI: https://doi.org/10.1111/hae.13519
Mannucci PM. Treatment of hemophilia - more amazing progress. N Engl J Med 2020;383:1068-70. DOI: https://doi.org/10.1056/NEJMe2024545
Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med 2020;383:1018-27. DOI: https://doi.org/10.1056/NEJMoa2002699
Peyvandi F, Garagiola I, Mannucci PM. Post-authorization pharmacovigilance for hemophilia in Europe and the USA: independence and transparency are keys. Blood Rev 2021;49:100828. DOI: https://doi.org/10.1016/j.blre.2021.100828
How to Cite
1.
Mannucci PM. Gene transfer in hemophilia A: not cogent yet. Bleeding Thromb Vascul Biol [Internet]. 2022 Apr. 20 [cited 2026 Jan. 21];1(1). Available from: https://www.btvb.org/btvb/article/view/32
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- Sara Mellano, Palestinian patients associations appeal on World Hemophilia Day , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 1 (2024)
- PO78 | Acquired hemophilia A as a paraneoplastic syndrome: two cases report on a rare coexistence , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Kamran Abbasi, Parveen Ali, Virginia Barbour, Kirsten Bibbins-Domingo, Marcel G.M. Olde Rikkert, Andy Haines, Ira Helfand, Richard Horton, Bob Mash, Arun Mitra, Carlos Monteiro, Elena N. Naumova, Eric J. Rubin, Tilman Ruff, Peush Sahni, James Tumwine, Paul Yonga, Chris Zielinski, Reducing the risks of nuclear war - The role of health professionals , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Pier Mannuccio Mannucci, Growing weapons to fight hemophilia , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- PO65 | Utilization of emicizumab in acquired hemophilia A: a case report , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO36 | Inhibitor titer at diagnosis and clinical course in acquired hemophilia A: a single-center experience , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- CO26 | Relationship between SMAD3 variants and non-aortic cardiovascular features , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Pier Mannuccio Mannucci, An ecological alliance against air pollution and cardiovascular disease , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Pier Mannuccio Mannucci, Growing weapons to fight hemophilia , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Pier Mannuccio Mannucci, Gene therapy for hemophilia B , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
